The Zacks Consensus Estimate of $3.22 billion is well within the company’s guidance range.Įndo Pharma expects to end 2012 with adjusted earnings in the range of $5.00-$5.20. The company continues to expect 2012 revenues in the range of $3.15-$3.30 billion.
Costs related to the acquisition of American Medical Systems contributed to the increase.Īpart from disclosing financial results, Endo Pharma reiterated its guidance for 2012. The remaining revenues came from services sales.Īdjusted operating expenses climbed 50.8% to approximately $282 million. Revenues came from the acquisition of American Medical Systems, a leading pelvic-health devices provider, in June 2011.
Revenues from devices sales came in at $130.0 million in the reported quarter. We remind investors that Qualitest Pharmaceuticals (a generic company) was purchased by Endo Pharma in 2010. Sales of pain drug Lidoderm climbed 11% to $210 million.Įndo Pharma’s generic segment (Qualitest) also performed well with sales climbing 8% to $145.0 million in the first quarter of 2012. Sales of osteoarthritis drug Voltaren Gel were absent during the first quarter of 2012, as opposed to $31.3 million a year-ago. To read this article on click here.Sales of pain drug Opana ER declined 4% to $81 million.
#ENDO PHARMA EARNINGS FREE#
Click to get this free reportĮndo International plc (ENDP) : Free Stock Analysis Reportīaudax Bio, Inc.
#ENDO PHARMA EARNINGS DOWNLOAD#
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.īaudax Bio, Inc.'s revenues are expected to be $0.77 million, up 285% from the year-ago quarter. This company is expected to post quarterly loss of $1.27 per share in its upcoming report, which represents a year-over-year change of +82.7%. (BXRX), has yet to report results for the quarter ended June 2022. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.Īnother stock from the same industry, Baudax Bio, Inc.
#ENDO PHARMA EARNINGS PLUS#
In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 36% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. While Endo has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Įndo shares have lost about 82.2% since the beginning of the year versus the S&P 500's decline of -13.1%. The company has topped consensus revenue estimates four times over the last four quarters. This compares to year-ago revenues of $713.83 million. In 2022 the company made a revenue of 2.31 B a decrease over the years 2021 revenue that were of 2.99 B.The revenue is the total amount of income that a. Over the last four quarters, the company has surpassed consensus EPS estimates four times.Įndo, which belongs to the Zacks Medical - Drugs industry, posted revenues of $569.11 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 9.01%. A quarter ago, it was expected that this health care company would post earnings of $0.44 per share when it actually produced earnings of $0.66, delivering a surprise of 50%. This quarterly report represents an earnings surprise of 118.75%. These figures are adjusted for non-recurring items. This compares to earnings of $0.65 per share a year ago. Endo International (ENDP) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share.
0 kommentar(er)
